Список литературы

1. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. (Internet)

2. Siegel RL., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Siegel%20RL%5BAuthor%5D&cauthor=true&cauthor_uid=25559415)Miller KD., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Miller%20KD%5BAuthor%5D&cauthor=true&cauthor_uid=25559415)Jemal A. Cancer statistics, 2015.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Jemal%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25559415)CA Cancer J Clin. - 2015. - V. 65, N 1. - P. 5 - 29. (https://www.ncbi.nlm.nih.gov/pubmed/25559415.)

3. Resnick KE., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Resnick%20KE%5BAuthor%5D&cauthor=true&cauthor_uid=19375789)Hampel H., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Hampel%20H%5BAuthor%5D&cauthor=true&cauthor_uid=19375789)Fishel R.et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Fishel%20R%5BAuthor%5D&cauthor=true&cauthor_uid=19375789)GynecolOncol. - 2009. - V. 114, N 1. - P. 128 - 34. (https://www.ncbi.nlm.nih.gov/pubmed/19375789.)

4. Van den Bosch T., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Van%20den%20Bosch%20T%5BAuthor%5D&cauthor=true&cauthor_uid=22078749)Coosemans A., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Coosemans%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22078749)Morina M.et al. Screening for uterine tumours.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Morina%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22078749)Best Pract Res ClinObstetGynaecol. - 2012. - V. 26, N 2. - P. 257 - 66. (https://www.ncbi.nlm.nih.gov/pubmed/22078749.)

5. Dinkelspiel HE., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Dinkelspiel%20HE%5BAuthor%5D&cauthor=true&cauthor_uid=23864861)Wright JD., (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wright%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=23864861)Lewin SN.et al. Contemporary clinical management of endometrial cancer.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Lewin%20SN%5BAuthor%5D&cauthor=true&cauthor_uid=23864861)ObstetGynecol Int. - 2013. - V. 2013. - ID 583891. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

6. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г.//М.: Издательская группа РОНЦ, 2014. - 226 с. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

7. Бохман Я.В. Руководство по онкогинекологии. - М.: Медицина, 1989. - 325 с. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

8. Kurman RJ., Carcangiu ML., Harrington CS., Young RH, eds. WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press; 2014. World Health Organization Classification of Tumors. 4th edition. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

9. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.//Int J Gynecol Obstet. - 2009. - V. 105, N 2. - P. 103 - 4. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

10. Amanta F., Mirzab M., Creutzbergc C. FIGO cancer report 2012. Cancer of the corpus uteri.//Int J Gynecol Obstet. - 2012. - V. 119, S 2. - P. S110 - S117. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

11. Cade TJ., Quinn MA., McNally OM. et al. Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment? Int J Gynecol Cancer. - 2010. - V. 20, N 7. - P. 1166 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/23864861.)

12. Ortashi O, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ortashi%20O%5BAuthor%5D&cauthor=true&cauthor_uid=17537566)Jain S, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Jain%20S%5BAuthor%5D&cauthor=true&cauthor_uid=17537566)Emannuel O. et al. Evaluation of the sensitivity, specificity, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer. A prospective study of 100 cases at the Dorset Cancer Centre.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Emannuel%20O%5BAuthor%5D&cauthor=true&cauthor_uid=17537566)Eur J ObstetGynecolReprod Biol. 2008 Apr; 137(2): 232 - 5. (https://www.ncbi.nlm.nih.gov/pubmed/17537566.)

13. Kitajima K, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Kitajima%20K%5BAuthor%5D&cauthor=true&cauthor_uid=21670955)Suzuki K, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Suzuki%20K%5BAuthor%5D&cauthor=true&cauthor_uid=21670955)Senda M, et al. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone?//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Senda%20M%5BAuthor%5D&cauthor=true&cauthor_uid=21670955)Ann Nucl Med. 2011 Aug; 25(7): 511 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/21670955.)

14. Antonsen SL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Antonsen%20SL%5BAuthor%5D&cauthor=true&cauthor_uid=23200916)Jensen LN, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Jensen%20LN%5BAuthor%5D&cauthor=true&cauthor_uid=23200916)Loft A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Loft%20A%5BAuthor%5D&cauthor=true&cauthor_uid=23200916) GynecolOncol. 2013 Feb; 128(2): 300 - 8. (https://www.ncbi.nlm.nih.gov/pubmed/23200916.)

15. Kwon JS, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Kwon%20JS%5BAuthor%5D&cauthor=true&cauthor_uid=21537049)Scott JL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Scott%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=21537049)Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Gilks%20CB%5BAuthor%5D&cauthor=true&cauthor_uid=21537049)J ClinOncol. 2011 Jun 1; 29(16): 2247 - 52. (https://www.ncbi.nlm.nih.gov/pubmed/21537049.)

16. Crispens MA. Endometrial and ovarian cancer in lynch syndrome.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Crispens%20MA%5BAuthor%5D&cauthor=true&cauthor_uid=23730224)Clin Colon Rectal Surg. 2012 Jun; 25(2): 97 - 102. (https://www.ncbi.nlm.nih.gov/pubmed/23730224.)

17. Walker JL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Walker%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=22291074)Piedmonte MR, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Piedmonte%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=22291074)Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Spirtos%20NM%5BAuthor%5D&cauthor=true&cauthor_uid=22291074) J ClinOncol. 2012 Mar 1; 30(7): 695 - 700 (https://www.ncbi.nlm.nih.gov/pubmed/22291074.)

18. Mourits MJ, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Mourits%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=20638901)Bijen CB, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bijen%20CB%5BAuthor%5D&cauthor=true&cauthor_uid=20638901)Arts HJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Arts%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=20638901)Lancet Oncol. 2010 Aug; 11(8): 763 - 71. (https://www.ncbi.nlm.nih.gov/pubmed/20638901.)

19. Wang HL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20HL%5BAuthor%5D&cauthor=true&cauthor_uid=23725166)Ren YF, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ren%20YF%5BAuthor%5D&cauthor=true&cauthor_uid=23725166)Yang J, et al. Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Yang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23725166)Asian Pac J Cancer Prev. 2013; 14(4): 2515 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/23725166.)

20. Krill LS, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Krill%20LS%5BAuthor%5D&cauthor=true&cauthor_uid=23528726)Bristow RE. Robotic surgery: gynecologic oncology.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Bristow%20RE%5BAuthor%5D&cauthor=true&cauthor_uid=23528726)Cancer J. 2013 Mar - Apr; 19(2): 167 - 76. (https://www.ncbi.nlm.nih.gov/pubmed/23528726.)

21. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrialcancer.//(https://www.ncbi.nlm.nih.gov/pubmed/23528726.)Obstet Gynecol. 2005 Aug; 106(2): 413 - 25. (https://www.ncbi.nlm.nih.gov/pubmed/16055605.)

22. Wright JD, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Wright%20JD%5BAuthor%5D&cauthor=true&cauthor_uid=19171707)Buck AM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Buck%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=19171707)Shah M, et al. Safety of ovarian preservation in premenopausal women with endometrial cancer.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Shah%20M%5BAuthor%5D&cauthor=true&cauthor_uid=19171707)J ClinOncol. 2009 Mar 10; 27(8): 1214 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/19171707.)

23. Koskas M, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Koskas%20M%5BAuthor%5D&cauthor=true&cauthor_uid=22959452)Bendifallah S, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bendifallah%20S%5BAuthor%5D&cauthor=true&cauthor_uid=22959452)Luton D, et al. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Luton%20D%5BAuthor%5D&cauthor=true&cauthor_uid=22959452)FertilSteril. 2012 Nov; 98(5): 1229 - 35. (https://www.ncbi.nlm.nih.gov/pubmed/22959452.)

24. Lee TS, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20TS%5BAuthor%5D&cauthor=true&cauthor_uid=23994534)Lee JY, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20JY%5BAuthor%5D&cauthor=true&cauthor_uid=23994534)Kim JW, et al. Outcomes of ovarian preservation in a cohort of premenopausal women with earlystage endometrial cancer: a Korean Gynecologic Oncology Group study.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Kim%20JW%5BAuthor%5D&cauthor=true&cauthor_uid=23994534)GynecolOncol. 2013 Nov; 131(2): 289 - 93. (https://www.ncbi.nlm.nih.gov/pubmed/23994534.)

25. Fishman DA, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Fishman%20DA%5BAuthor%5D&cauthor=true&cauthor_uid=8626131) Roberts KB, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Roberts%20KB%5BAuthor%5D&cauthor=true&cauthor_uid=8626131)Chambers JT, et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Chambers%20JT%5BAuthor%5D&cauthor=true&cauthor_uid=8626131) GynecolOncol. 1996 May; 61(2): 189 - 96. (https://www.ncbi.nlm.nih.gov/pubmed/8626131.)

26. Coon D, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Coon%20D%5BAuthor%5D&cauthor=true&cauthor_uid=18258388)Beriwal S, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Beriwal%20S%5BAuthor%5D&cauthor=true&cauthor_uid=18258388)Heron DE, et al. High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Heron%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=18258388)Int J RadiatOncolBiol Phys. 2008 Jul 1; 71(3): 779 - 83. (https://www.ncbi.nlm.nih.gov/pubmed/18258388.)

27. Niazi TM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Niazi%20TM%5BAuthor%5D&cauthor=true&cauthor_uid=16099598)Souhami L, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Souhami%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16099598)Portelance L, et al. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I - II endometrial carcinoma.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Portelance%20L%5BAuthor%5D&cauthor=true&cauthor_uid=16099598)Int J RadiatOncolBiol Phys. 2005 Nov 15; 63(4): 1108 - 13. (https://www.ncbi.nlm.nih.gov/pubmed/16099598.)

28. Gunderson CC, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Gunderson%20CC%5BAuthor%5D&cauthor=true&cauthor_uid=22245711)Fader AN, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Fader%20AN%5BAuthor%5D&cauthor=true&cauthor_uid=22245711) Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Carson%20KA%5BAuthor%5D&cauthor=true&cauthor_uid=22245711) GynecolOncol. 2012 May; 125(2): 477 - 82. (https://www.ncbi.nlm.nih.gov/pubmed/22245711.)

29. Baker J, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Baker%20J%5BAuthor%5D&cauthor=true&cauthor_uid=22196499)Obermair A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Obermair%20A%5BAuthor%5D&cauthor=true&cauthor_uid=22196499)Gebski V, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Gebski%20V%5BAuthor%5D&cauthor=true&cauthor_uid=22196499) GynecolOncol. 2012 Apr; 125(1): 263 - 70. (https://www.ncbi.nlm.nih.gov/pubmed/22196499.)

30. Colombo N., Creutzberg C., Amant F. et al. ESMO-ESGO-ESTRO Consensus conference on endometrial cancer. Diagnosis, treatment and follow-up. // Int J Gynecol Cancer. - 2016. - V. 26, N 1. - P. 2 - 30. (https://www.ncbi.nlm.nih.gov/pubmed/22196499.)

31. Kitchener H, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Kitchener%20H%5BAuthor%5D&cauthor=true&cauthor_uid=19070889) Swart AM, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Swart%20AM%5BAuthor%5D&cauthor=true&cauthor_uid=19070889)Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Qian%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=19070889)Lancet. 2009 Jan 10; 373(9658): 125 - 36. (https://www.ncbi.nlm.nih.gov/pubmed/19070889.)

32. Benedetti Panici P1, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Benedetti%20Panici%20P%5BAuthor%5D&cauthor=true&cauthor_uid=19033573)Basile S, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Basile%20S%5BAuthor%5D&cauthor=true&cauthor_uid=19033573) Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Maneschi%20F%5BAuthor%5D&cauthor=true&cauthor_uid=19033573)J Natl Cancer Inst. 2008 Dec 3; 100(23): 1707 - 16. (https://www.ncbi.nlm.nih.gov/pubmed/19033573.)

33. Boente MP1, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Boente%20MP%5BAuthor%5D&cauthor=true&cauthor_uid=8112639)Yordan EL Jr, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Yordan%20EL%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=8112639)McIntosh DG, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=McIntosh%20DG%5BAuthor%5D&cauthor=true&cauthor_uid=8112639)GynecolOncol. 1993 Dec; 51(3): 316 - 22. (https://www.ncbi.nlm.nih.gov/pubmed/8112639.)

34. Sartori E1, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Sartori%20E%5BAuthor%5D&cauthor=true&cauthor_uid=11906545)Gadducci A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Gadducci%20A%5BAuthor%5D&cauthor=true&cauthor_uid=11906545)Landoni F, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy.//(https://www.ncbi.nlm.nih.gov/pubmed/?term=Landoni%20F%5BAuthor%5D&cauthor=true&cauthor_uid=11906545) Int J Gynecol Cancer. 2001 Nov-Dec; 11(6): 430 - 7. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

35. Bouchard M., Nadeau S., Gingras L. et al. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-modulated radiotherapy.//Int J RadiatOncolBiolPhys 2008; 71: 1343 - 1350 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

36. Beriwal S., Jain S.K., Heron D.E., et al. Clinical outcome with adjuavant treatment of endometrial carcinoma using intensity-modulated radiation therapy.//GynecolOncol 2006; 102: 195 - 199 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

37. Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomisedPost Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012; 48: 1638 - 1648. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

38. Roper B, Astner ST, Heydemann-Obradovic A, et al. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. GynecolOncol 2007; 107: 541 - 548. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

39. Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J ClinOncol 2009; 27: 3547 - 3556. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

40. Le T, Menard C, Samant R, et al. Longitudinal assessments of quality of life in endometrial cancer patients: effect of surgical approach and adjuvant radiotherapy. Int J RadiatOncolBiolPhys 2009; 75: 795 - 802. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

41. Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an american society for radiation oncology evidence-based guideline. PractRadiatOncol. 2014; 4: 137 - 144. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

42. Elshaikh MA, Al-Wahab Z, Mahdi H, et al. Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. GynecolOncol 2015; 136: 235 - 239. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

43. McMeekin DS, Filiaci V, Aghajanian C, et al. A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial [abstract]. SGO Annual Meeting: Society for Gynecologic Oncology; 2014. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

44. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010; 46: 2422 - 2431 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

45. Johnson N, Bryant A, Miles T, et al. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011: CD003175. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

46. Gibbons S, Martinez A, Schray M, et al. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J RadiatOncolBiolPhys 1991; 21: 1019 - 1025. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

47. Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. GynecolOncol 1983; 16: 365 - 373. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

48. Abaid LN, Rettenmaier MA, Brown JV, 3rd, et al. Sequential chemotherapy and radiotherapy as sandwich therapy for the treatment of high risk endometrial cancer. J GynecolOncol 2012; 23: 22 - 27. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

49. Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. GynecolOncol 2011; 121: 112 - 117 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

50. Ray M, Fleming G. Management of advanced-stage and recurrent endometrial cancer. SeminOncol 2009; 36: 145 - 154. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

51. Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007; 18: 409 - 420. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

52. Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. GynecolOncol 2010; 119: 538 - 542. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

53. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J ClinOncol 2004; 22: 2159 - 2166. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

54. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study [abstract]. Gynecologic Oncology 2012; 125: 771. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

55. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. GynecolOncol 2004; 92: 10 - 14. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

56. Altman AD, Thompson J, Nelson G, et al. Use of aromatase inhibitors as first-and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J ObstetGynaecol Can 2012; 34: 664 - 672. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

57. Altman AD, Thompson J, Nelson G, et al. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J ObstetGynaecol Can 2012; 34: 664 - 672. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

58. Barker LC, Brand IR, Crawford SM. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009; 25: 1105 - 1109. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

59. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. GynecolOncol 2004; 92: 4 - 9 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

60. Herzog TJ. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? GynecolOncol 2004; 92: 1 - 3. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

61. Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. GynecolOncol 2007; 106: 325 - 333. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

62. Wadler S, Levy DE, Lincoln ST, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J ClinOncol 2003; 21: 2110 - 2114 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

63. Traina TA, Sabbatini P, Aghajanian C, Dupont J. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. GynecolOncol 2004; 95: 235 - 241 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

64. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17: 964 - 978. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

65. Miller DS, Blessing JA, Lentz SS, Waggoner SE. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. GynecolOncol 2002; 87: 247 - 251. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

66. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J ClinOncol 2002; 20: 2360 - 2364 (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

67. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study. J ClinOncol 2011; 29: 2259 - 2265. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

68. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009; 16: 46 - 52. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

69. Fader AN, Nagel C, Axtell AE, et al. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. GynecolOncol 2009; 112: 558 - 562. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

70. Goldberg H, Miller RC, Abdah-Bortnyak R, et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). GynecolOncol 2008; 108: 298 - 305. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

71. Sutton G, Axelrod JH, Bundy BN, et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. GynecolOncol 2006; 100: 349 - 354. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

72. Boruta DM, 2nd, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. GynecolOncol 2009; 115: 142 - 153. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

73. Olawaiye AB, Boruta DM, 2nd. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. GynecolOncol 2009; 113: 277 - 283. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

74. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009; 16: 46 - 52. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

75. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. CurrOpinObstetGynecol 2010; 22: 21 - 29. (https://www.ncbi.nlm.nih.gov/pubmed/11906545.)

76. Barlin JN, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Barlin%20JN%5BAuthor%5D&cauthor=true&cauthor_uid=20434198)Puri I, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Puri%20I%5BAuthor%5D&cauthor=true&cauthor_uid=20434198)Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Bristow%20RE%5BAuthor%5D&cauthor=true&cauthor_uid=20434198)Gynecol Oncol. 2010 Jul; 118(1): 14 - 8. (https://www.ncbi.nlm.nih.gov/pubmed/20434198)

77. Lambrou NC, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lambrou%20NC%5BAuthor%5D&cauthor=true&cauthor_uid=15196860)G mezMar n O, (https://www.ncbi.nlm.nih.gov/pubmed/?term=G%C3%B3mezMar%C3%ADn%20O%5BAuthor%5D&cauthor=true&cauthor_uid=15196860)Mirhashemi R. et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Mirhashemi%20R%5BAuthor%5D&cauthor=true&cauthor_uid=15196860)Gynecol Oncol. 2004 Jun; 93(3): 653 - 8. (https://www.ncbi.nlm.nih.gov/pubmed/15196860)

78. Secord AA, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Secord%20AA%5BAuthor%5D&cauthor=true&cauthor_uid=19560193)Havrilesky LJ, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Havrilesky%20LJ%5BAuthor%5D&cauthor=true&cauthor_uid=19560193)O"Malley DM, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. (https://www.ncbi.nlm.nih.gov/pubmed/?term=O)Gynecol Oncol. 2009 Sep; 114(3): 4427. (https://www.ncbi.nlm.nih.gov/pubmed/19560193)

79. Jhingran A, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Jhingran%20A%5BAuthor%5D&cauthor=true&cauthor_uid=12873682)Burke TW, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Burke%20TW%5BAuthor%5D&cauthor=true&cauthor_uid=12873682)Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Eifel%20PJ%5BAuthor%5D&cauthor=true&cauthor_uid=12873682)Int J Radiat Oncol Biol Phys. 2003 Aug 1; 56(5): 1366 - 72. (https://www.ncbi.nlm.nih.gov/pubmed/12873682)

80. Creutzberg CL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Creutzberg%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=12713981)van Putten WL, (https://www.ncbi.nlm.nih.gov/pubmed/?term=van%20Putten%20WL%5BAuthor%5D&cauthor=true&cauthor_uid=12713981)Koper PC, Survival after relapse in patients with endometrial cancer: results from a randomized trial. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Koper%20PC%5BAuthor%5D&cauthor=true&cauthor_uid=12713981) Gynecol Oncol. 2003 May; 89(2): 201 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/12713981)

81. Lee JH, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20JH%5BAuthor%5D&cauthor=true&cauthor_uid=21606818)Dubinsky T, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Dubinsky%20T%5BAuthor%5D&cauthor=true&cauthor_uid=21606818)Andreotti RF, ACR appropriateness Criteria(R) pretreatment evaluation and follow-up of endometrial cancer of the uterus. (https://www.ncbi.nlm.nih.gov/pubmed/?term=Andreotti%20RF%5BAuthor%5D&cauthor=true&cauthor_uid=21606818)Ultrasound Q. 2011 Jun; 27(2): 139 - 45. (https://www.ncbi.nlm.nih.gov/pubmed/21606818)